Organon & Co. OGN

OGN Company Overview

Organon & Co. is a global healthcare company focused on improving women’s health, while also maintaining a diversified portfolio of established pharmaceuticals and biosimilars. The company operates within the pharmaceuticals and healthcare industries, with a strategic emphasis on areas that have historically received less research and commercial focus. Organon generates revenue primarily through prescription medicines, leveraging both legacy brands and newer growth products.

The company was formed in 2021 as a spin-off from Merck & Co., Inc., inheriting a portfolio of established medicines and global commercial infrastructure. Since becoming an independent publicly traded company, Organon has positioned itself as a scaled operator in women’s health with durable cash flows from mature brands, using this foundation to invest in innovation, partnerships, and acquisitions.